Try our Advanced Search for more refined results
September 23, 2020
JANSSEN PHARMACEUTICALS, INC. et al v. MYLAN LABORATORIES LIMITED et al
Case Number:
2:20-cv-13103
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
May 23, 2023
Janssen Prevails In Patent Battle With Mylan Over Generics
A New Jersey federal judge has ruled that Mylan cannot pursue a generic version of Janssen's schizophrenia drug Invega Trinza, finding that although the patent for Trinza has expired, Mylan's generic would cause physicians to infringe another Janssen patent covering the drug's dosing regimen, according to an order unsealed Tuesday.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login